Kirby McInerney LLP Alerts Investors Who Acquired Beta Bionics, Inc. BBNX Securities Between July 30, 2025 and February 24, 2026 of Pending Lawsuit
Kirby McInerney LLP issued a notice reminding Beta Bionics (NASDAQ: BBNX) investors of the November 3, 2026 lead-plaintiff deadline in a pending federal securities class action covering purchases from July 30, 2025 through February 24, 2026. The suit alleges Beta Bionics concealed that its iLet insulin pump was malfunctioning and dosing dangerously high insulin levels, that the FDA raised these issues in a Form 483, and that thousands of customer complaints including hundreds of life-threatening events were back-filed with the FDA.
Key figures
- Jan 2026 drop
- 37% drop to $20.14 on Jan 9, 2026 after Q4 patient-start miss
- Class period end
- 2026-02-24
- Feb 25 2026 close
- $12.89 (-3.7%) after FDA warning-letter release
- Jan 30 2026 close
- $13.83 (-6.5%) after 8-K revealing FDA warning letter
- Class period start
- 2025-07-30
- Lead plaintiff deadline
- 2026-11-03
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.